Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

JPMorgan ups Aberdeen to 'overweight', places shares on 'positive catalyst watch'

(Sharecast News) - JPMorgan Cazenove upgraded Aberdeen on Tuesday to 'overweight' from 'neutral' and placed the stock on 'positive catalyst watch' ahead of results, sending shares in the asset manager surging. The bank said its analysis suggests that flows in the Adviser vector might soon turn positive thanks to a new competitive pricing structure and improving customer satisfaction.

"Furthermore, we expect that the strong momentum recorded by interactive investor (ii) in recent quarters will accelerate further, and that the platform will continue to win market share thanks to its best-in-class pricing and compelling offering," JPM said.

It said that stronger customer growth and growing SIPP penetration could also increase cash balances on the platform and drive an increase in treasury income and earnings per share.

"Our analysis suggests that these tailwinds are imminent, and we place the stock on positive catalyst watch ahead of the 1H results (30th July)," it said.

JPM said it is 2%/9% above Bloomberg EPS consensus for FY26/27 and it also sees scope for an expansion in multiple as these tailwinds unfold.

At 1005 BST, the shares were up 7.1% at 197.20p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.